Vivian Rexroad, PharmD

CRS:

JHU

Role:

Pharmacy

Position:

Pharmacist, PharmD, Investigational Drug Pharmacy

Email:

vrexroa@jhmi.edu
  • Network Pharmacist, IMPAACT Leadership
  • Member, IMPAACT Multidisciplinary Protocol Review Group
  • Protocol team member for IMPAACT 1078, IMPAACT 1114,  IMPAACT 2000 and IMPAACT 2011
  • General Member (Pharmacist), Protocol Development and Implementation Subcommittee of the SMCCC (Mar 2016-Nov 2019)
  • Member, Pharmacy Working Group of the Protocol Development and Implementation Subcommittee (Mar 2016-Nov 2019)
  • Protocol team member, IMPAACT 2012
  • Protocol team member, IMPAACT 2013
  • Protocol team member, IMPAACT 2018
  • Protocol team member, IMPAACT 2021

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

A5320: Viral Hepatitis C Infection Long-term Cohort Study...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More